~~<i id='18B5F3CD9D'><strike id='18B5F3CD9D'><tt id='18B5F3CD9D'><pre id='18B5F3CD9D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：entertainment 2025-09-27 22:18:29 - browse：73

Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. But some in the industry worry about the unintended consequences of overreliance.

Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.

When the American Society of Health-System Pharmacists surveyed its members this past summer, 59% said they increased purchases from compounders because of drug shortages.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Hospital price transparency does save money, advocate argues

leisure time

explore

entertainment

leisure time

hotspot

Wikipedia

Photoillustration:STATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiot

WSS

STAT Summit: GSK CEO on pharma giant's new direction

Ohio still needs to do more to protect the right to abortion

STAT Summit: GSK CEO on pharma giant's new direction

White House drug czar issues call for 'recovery

HHS leader on health, climate change and biopharma emissions

Ventyx halts psoriasis drug development after lackluster trial results

focus

explore

leisure time

In Memoriam: Notable people who died in 2023

Lawmakers consider Medicare pay reforms for doctors

After affirmative action ruling, medical educators look to 'holistic review'

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Wildfire smoke exposes gaps in outdoor worker protections

Lawmakers consider Medicare pay reforms for doctors

Moonlake's readout produced a cash windfall. Risks remain

Studies point to risks of excluding people with obesity from drug trials

What does generative AI mean for health care? We asked experts

STAT Summit: GSK CEO on pharma giant's new direction

explore

HHS leader on health, climate change and biopharma emissions

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

STAT Summit: GSK CEO on pharma giant's new direction

What is STAT's opinion section for?

Pharmacists can make shortage drugs, but at what cost?

NIH chief: government has fallen behind pharma on clinical trials

entertainment

leisure time

hotspot

Wikipedia